Usefulness of Highly Sensitive Troponin as a Predictor of Short-Term Outcome in Patients with Diabetes Mellitus and Stable Coronary Artery Disease (from the ARTEMIS Study)

American Journal of Cardiology

Volumn 117, Issue 4, 2016, Pages 515-521

  Lepojärvi, E Samuli ^a   Piira, Olli Pekka ^a   Kiviniemi, Antti M ^a   Miettinen, Johanna A ^a   Kenttä, Tuomas ^a   Ukkola, Olavi ^a   Tulppo, Mikko P ^a   Huikuri, Heikki V ^a   Junttila, M Juhani ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; GLUCOSE; LIPID; SOLUBLE SUPPRESSOR OF TUMORIGENICITY 2 PROTEIN; TROPONIN T; UNCLASSIFIED DRUG; TROPONIN;

AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE MARKER; FEMALE; FOLLOW UP; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PRIORITY JOURNAL; BLOOD; CAUSE OF DEATH; COMPLICATION; EPIDEMIOLOGY; FINLAND; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TIME FACTOR; TRENDS;

AGED; BIOMARKERS; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TROPONIN;

EID: 84958935218     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.11.038     Document Type: Article

References (26)

1. T. Omland, M.A. Pfeffer, S.D. Solomon, J.A. De Lemos, H. Røsjø, J. Šaltytė Benth, A. Maggioni, M.J. Domanski, J.L. Rouleau, M.S. Sabatine, E. Braunwald PEACE Investigators Prognostic value of cardiac troponin i measured with a highly sensitive assay in patients with stable coronary artery disease J Am Coll Cardiol 61 2013 1240 1249
2. T. Omland, J.A. De Lemos, M.S. Sabatine, C.A. Christophi, M.M. Rice, K.A. Jablonski, S. Tjora, M.J. Domanski, B.J. Gersh, J.L. Rouleau, M.A. Pfeffer, E. Braunwald Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators A sensitive cardiac troponin T assay in stable coronary artery disease N Engl J Med 361 2009 2538 2547
3. O.W. Oluleye, A.R. Folsom, V. Nambi, P.L. Lutsey, C.M. Ballantyne ARIC Study Investigators Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality Ann Epidemiol 23 2013 66 73
4. B. Dieplinger, M. Egger, M. Haltmayer, M.E. Kleber, H. Scharnagl, G. Silbernagel, R.A. de Boer, W. Maerz, and T. Mueller Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study Clin Chem 60 2014 530 540
5. D.A. Pascual-Figal, J. Ordoñez-Llanos, P.L. Tornel, R. Vázquez, T. Puig, M. Valdés, J. Cinca, A.B. de Luna, A. Bayes-Genis MUSIC Investigators Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 2009 2174 2179
6. A. Bayes-Genis, M. de Antonio, J. Vila, J. Penafiel, A. Galan, J. Barallat, E. Zamora, A. Urrutia, and J. Lupón Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3 J Am Coll Cardiol 63 2014 158 166
7. D.J. Lok, S.I. Lok, P.W. Bruggink-André De La Porte, E. Badings, E. Lipsic, J. Van Wijngaarden, R.A. de Boer, D.J. van Vedlhuisen, and P. van der Meer Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure Clin Res Cardiol 102 2013 103 110
8. J.E. Ho, C. Liu, A. Lyass, P. Courchesne, M.J. Pencina, R.S. Vasan, M.G. Larson, and D. Levy Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
9. R.A. de Boer, D.J. Lok, T. Jaarsma, P. Van Der Meer, A.A. Voors, H.L. Hillege, and D.J. van Veldhuisen Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
10. M.J. Junttila, P. Barthel, R.J. Myerburg, T.H. Mäkikallio, A. Bauer, K. Ulm, A. Kiviniemi, M. Tulppo, J.S. Perkiömäki, G. Schmidt, and H.V. Huikuri Sudden cardiac death after myocardial infarction in patients with type 2 diabetes Heart Rhythm 7 2010 1396 1403
11. W.B. Kannel, and D.L. McGee Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study Diabetes Care 2 1979 120 126
12. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial Diabetes Care 16 1993 434 444
13. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 Suppl. 2 2001 S14 S21
14. L. Rydén, P.J. Grant, S.D. Anker, C. Berne, F. Cosentino, N. Danchin, C. Deaton, J. Escaned, H.P. Hammes, H. Huikuri, M. Marre, N. Marx, L. Mellbin, J. Ostergren, C. Patrono, P. Seferovic, M.S. Uva, M.R. Taskinen, M. Tendera, J. Tuomilehto, P. Valensi, J.L. Zamorano ESC Committee for Practice Guidelines (CPG) J.L. Zamorano, S. Achenbach, H. Baumgartner, J.J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A.W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M.F. Piepoli, P. Ponikowski, P.A. Sirnes, J.L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, and S. Windecker ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur Heart J 34 2013 3035 3087
15. J.J. Karjalainen, A.M. Kiviniemi, A.J. Hautala, O.P. Piira, E.S. Lepojärvi, M.A. Peltola, O.H. Ukkola, P.S. Hedberg, H.V. Huikuri, and M.P. Tulppo Determinants and prognostic value of cardiovascular autonomic function in coronary artery disease patients with and without type 2 diabetes Diabetes Care 37 2014 286 294
16. WHO Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1: Diagnosis and Classification of Diabetes Mellitus 1999 WHO, Department of Noncommunicable Disease Surveillance Geneva
17. M.A. Hlatky, P. Greenland, D.K. Arnett, C.M. Ballantyne, M.H. Criqui, M.S. Elkind, A.S. Go, F.E. Harrell Jr., Y. Hong, B.V. Howard, V.J. Howard, P.Y. Hsue, C.M. Kramer, J.P. McConnell, S.L. Normand, C.J. O'Donnell, S.C. Smith Jr., P.W. Wilson American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
18. M.J. Pencina, R.B. D'Agostino, and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
19. C. Hage, P. Lundman, L. Rydén, and L. Mellbin Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes Eur J Prev Cardiol 20 2013 549 554
20. S.M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
21. K. Malmberg, S. Yusuf, H.C. Gerstein, J. Brown, F. Zhao, D. Hunt, L. Piegas, J. Calvin, M. Keltai, and A. Budaj Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Circulation 102 2000 1014 1019
22. J.T. Saunders, V. Nambi, J.A. de Lemos, L.E. Chambless, S.S. Virani, E. Boerwinkle, R.C. Hoogeveen, X. Liu, B.C. Astor, T.H. Mosley, A.R. Folsom, G. Heiss, J. Coresh, and C.M. Ballantyne Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study Circulation 123 2011 1367 1376
23. S. Lyngbæk, P. Winkel, J.P. Gøtze, J. Kastrup, C. Gluud, H.J. Kolmos, E. Kjøller, G.B. Jensen, J.F. Hansen, P. Hildebrandt, J. Hilden CLARICOR Trial Group Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide Eur J Prev Cardiol 21 2014 1275 1284
24. J. Rubin, K. Matsushita, C.M. Ballantyne, R. Hoogeveen, J. Coresh, and E. Selvin Chronic hyperglycemia and subclinical myocardial injury J Am Coll Cardiol 59 2012 484 489
25. B.M. Everett, M.M. Brooks, H.E. Vlachos, B.R. Chaitman, R.L. Frye, D.L. Bhatt BARI 2D Study Group Troponin and cardiac events in stable ischemic heart disease and diabetes N Engl J Med 373 2015 610 620
26. L. Scheven, P.E. De Jong, H.L. Hillege, H.J. Lambers Heerspink, L.J. Van Pelt, J.E. Kootstra, S.J. Bakker, R.T. Gansevoort PREVEND study group High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate Eur Heart J 33 2012 2272 2281